enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of “Hold” from Brokerages

Posted by George Bondi on Jun 14th, 2026

enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been given a consensus recommendation of “Hold” by the fourteen brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $12.6818.

A number of equities analysts have recently issued reports on ENGN shares. Wall Street Zen downgraded shares of enGene from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Wells Fargo & Company reissued an “equal weight” rating and set a $2.00 target price (down from $25.00) on shares of enGene in a research report on Friday, May 8th. Raymond James Financial cut shares of enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 target price for the company. in a research report on Friday, May 8th. WBB Securities began coverage on shares of enGene in a research report on Monday, April 13th. They set a “buy” rating and a $21.50 target price for the company. Finally, Citizens Jmp cut shares of enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th.

View Our Latest Research Report on enGene

Institutional Investors Weigh In On enGene

A number of hedge funds and other institutional investors have recently bought and sold shares of ENGN. Cresset Asset Management LLC purchased a new stake in enGene during the second quarter valued at approximately $36,000. Paloma Partners Management Co purchased a new stake in enGene during the second quarter valued at approximately $38,000. Raymond James Financial Inc. lifted its position in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares during the last quarter. Hudson Bay Capital Management LP purchased a new stake in enGene during the third quarter valued at approximately $76,000. Finally, PFS Partners LLC lifted its position in enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after acquiring an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Price Performance

NASDAQ ENGN opened at $1.62 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.75 and a current ratio of 11.75. The firm’s 50 day moving average price is $4.41 and its 200-day moving average price is $7.24. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The company has a market cap of $108.52 million, a PE ratio of -0.72 and a beta of -0.30.

enGene Company Profile

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.